Related Experiment Video
Updated: Jan 13, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
Does Genetic Variation in Detoxification Capacity Influence Hepatic Biomarker Responses to a Liver Support
Markus Schauer1,2, Susanne Mair2, Michael Keiner1
1Department of Sport Science, German University of Health & Sport (DHGS), 85737 Ismaning, Germany.
Abstract:
Genetic polymorphisms contribute to inter-individual variation in liver detoxification, influencing susceptibility to exposures and responses to interventions. While urinary biomarkers reflect Phase II activity, the impact of genotype on supplementation response remains unclear. In a pilot, prospective, open-label cohort study, 30 Austrian adults completed an 8-week multi-ingredient liver support supplementation regimen (e.g., glutathione, N-acetylcysteine, α-lipoic acid). First-morning urine was collected at baseline and follow-up for measurement of D-glucaric acid, mercapturic acids, and creatinine. Dried blood spots were genotyped for polymorphisms in detoxification genes (CYP1A1, GSTM1, GSTP1, GSTT1, and NQO1), and participants were stratified into normal (NDC) or limited (LDC) detoxification capacity groups. Adherence was monitored through logs, mid-study interviews, and product counts. The intervention led to modest reductions in body weight (-0.87 kg, p < 0.05) and BMI (-0.31 kg/m2, p < 0.05), and significant increases in urinary D-glucaric acid (p < 0.05) and mercapturic acids (p < 0.01), with consistent responses across detoxification genotype groups (p > 0.05). The pattern of biomarker responses based on clinically defined categories did not differ significantly between the study groups (adjusted odds ratio = 2.88, p > 0.05). The observed increases in urinary biomarkers and reductions in weight and BMI are consistent with potential modulation of detoxification pathways following liver support supplementation, independent of genetic polymorphisms influencing detoxification capacity.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Hepatic Drug Excretion: Influencing Factors
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Factors Affecting Drug Biotransformation: Biological
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...

